Device Trial Radar · NCT07928505
Safety and Effectiveness Assessment of AneuFix Injectable Polymer Sac Filling to Assure Long-term Durability of EVAR.
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jan 15, 2027
Primary completion
Dec 31, 2029
Study completion Dec 3, 2033
Sponsor
- Lead sponsor
- TripleMed B.V.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Xper Research; Clinfidence B.V.
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated device
- No
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety and effectiveness of adding AneuFix Injectable Polymer sac filling to standard endovascular aneurysm repair (EVAR) in patients with an infrarenal abdominal aortic aneurysm (AAA) who are at high risk of developing a Type II endoleak after EVAR. The study will include adult men and women who are candidates for elective EVAR and meet predefined imaging criteria indicating a high risk of post-procedural Type II endoleak. The main questions it aims to answer are: * Does the addition of AneuFix Injectable Polymer to standard EVAR reduce the occurrence of Type II endoleaks, prevent aneurysm sac growth, and reduce the need for AAA-related reinterventions within 12 months after treatment? * Is treatment with AneuFix Injectable Polymer safe, as measured by the rate of major adverse events within 30 days after the procedure? Researchers will compare EVAR plus AneuFix Injectable Polymer sac filling with standard EVAR alone to determine whether sac filling improves aneurysm-related outcomes and reduces complications associated with persistent blood flow into the aneurysm sac following EVAR. Participants will: * Undergo screening assessments, including review of medical history, imaging studies, and eligibility criteria. * Be randomly assigned in a 2:1 ratio to receive either: * Standard EVAR with AneuFix Injectable Polymer sac filling, or * Standard EVAR alone. * Attend follow-up visits at approximately 1 month, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years after treatment. * Undergo imaging assessments, including CT angiography and ultrasound or magnetic resonance angiography, to evaluate the presence of endoleaks, aneurysm sac size, and other aneurysm-related outcomes. * Be monitored for adverse events, reinterventions, aneurysm-related complications, and survival throughout the 5-year follow-up period. * Complete quality-of-life questionnaires at selected study visits. This multicenter, randomized, controlled study plans to enroll approximately 150 participants at sites across Europe and follow them for up to 5 years after treatment.
Conditions
- Endoleak After Endovascular Aneurysm Repair
- Aortic Aneurysm Abdominal
Interventions
AneuFix Injectable PolymerDevice
Injectable polymer intended for delivery into the abdominal aortic aneurysm sac during EVAR to provide aneurysm sac filling and occlusion of blood flow pathways associated with Type II endoleak formation.
Endovascular AneuRysm Repair (EVAR)Procedure
Endovascular placement of a commercially available stent graft to exclude the abdominal aortic aneurysm from systemic blood flow.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite Treatment Success at 12 MonthsTime frame: 12 Months
- Major Adverse Event (MAE) rate within the 30-day follow-up period after the procedureTime frame: 30 Days Post-Procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Amsterdam UMC
Amsterdam, North Holland, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.